These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27021324)

  • 21. Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.
    Jeong W; Snell GI; Levvey BJ; Westall GP; Morrissey CO; Wolfe R; Ivulich S; Neoh CF; Slavin MA; Kong DCM
    J Antimicrob Chemother; 2018 Mar; 73(3):748-756. PubMed ID: 29211913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis.
    Luong ML; Chaparro C; Stephenson A; Rotstein C; Singer LG; Waters V; Azad S; Keshavjee S; Tullis E; Husain S
    Transplantation; 2014 Feb; 97(3):351-7. PubMed ID: 24305637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.
    Groll AH; Abdel-Azim H; Lehrnbecher T; Steinbach WJ; Paschke A; Mangin E; Winchell GA; Waskin H; Bruno CJ
    Int J Antimicrob Agents; 2020 Sep; 56(3):106084. PubMed ID: 32682946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.
    Yi WM; Schoeppler KE; Jaeger J; Mueller SW; MacLaren R; Fish DN; Kiser TH
    Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):60. PubMed ID: 28893246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men.
    Krishna G; Sansone-Parsons A; Kantesaria B
    Curr Med Res Opin; 2007 Jun; 23(6):1415-22. PubMed ID: 17559737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.
    Leclerc E; Combarel D; Uzunov M; Leblond V; Funck-Brentano C; Zahr N
    Sci Rep; 2018 Jan; 8(1):1681. PubMed ID: 29374234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation.
    Van Daele R; Spriet I; Maertens J
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):539-550. PubMed ID: 32478597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals.
    Heimann SM; Penack O; Heinz WJ; Rachow T; Egerer G; Kessel J; Claßen AY; Vehreschild JJ
    Int J Infect Dis; 2019 Jun; 83():130-138. PubMed ID: 30978465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.
    Gautier-Veyret E; Bolcato L; Roustit M; Weiss S; Tonini J; Brenier-Pinchart MP; Cornet M; Thiebaut-Bertrand A; Stanke-Labesque F
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Posaconazole plasma concentrations in critically ill patients.
    Ray J; Campbell L; Rudham S; Nguyen Q; Marriott D
    Ther Drug Monit; 2011 Aug; 33(4):387-92. PubMed ID: 21654350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: The Alfred's experience.
    Jeong W; Snell GI; Levvey BJ; Westall GP; Morrissey CO; Ivulich S; Neoh CF; Slavin MA; Kong DCM
    J Antimicrob Chemother; 2017 Jul; 72(7):2089-2092. PubMed ID: 28369489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients.
    Ju C; Lian Q; Chen A; Zhao B; Zhou S; Cai Y; Xie H; Wei L; Li S; He J
    Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36036471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
    Krishna G; Sansone-Parsons A; Martinho M; Kantesaria B; Pedicone L
    Antimicrob Agents Chemother; 2007 Mar; 51(3):812-8. PubMed ID: 17210771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.
    Märtson AG; Veringa A; van den Heuvel ER; Bakker M; Touw DJ; van der Werf TS; Span LFR; Alffenaar JC
    Mycoses; 2019 Aug; 62(8):698-705. PubMed ID: 31145490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.
    Vicenzi EB; Calore E; Decembrino N; Berger M; Perruccio K; Carraro F; Rossin S; Putti MC; Molinaro M; Tridello G; Cesaro S
    Eur J Haematol; 2018 Mar; 100(3):315-322. PubMed ID: 29240266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
    Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
    Wu X; Clancy CJ; Rivosecchi RM; Zhao W; Shields RK; Marini RV; Venkataramanan R; Nguyen MH
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area.
    Vanstraelen K; Colita A; Bica AM; Mols R; Augustijns P; Peersman N; Vermeersch P; Annaert P; Spriet I
    Pediatr Infect Dis J; 2016 Feb; 35(2):183-8. PubMed ID: 26544987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
    Arrieta AC; Sung L; Bradley JS; Zwaan CM; Gates D; Waskin H; Carmelitano P; Groll AH; Lehrnbecher T; Mangin E; Joshi A; Kartsonis NA; Walsh TJ; Paschke A
    PLoS One; 2019; 14(3):e0212837. PubMed ID: 30913226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posaconazole therapy in children with cystic fibrosis and Aspergillus-related lung disease.
    Patel D; Popple S; Claydon A; Modha DE; Gaillard EA
    Med Mycol; 2020 Jan; 58(1):11-21. PubMed ID: 30877757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.